Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chip-seq analysis after dBRD9-A treatment in human multiple myeloma cell line OPM2

ABSTRACT: Chip-seq analysis after dBRD9-A treatment in human multiple myeloma cell line OPM2

PROVIDER: PRJNA810496 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18148044_1.fastq.gz	Fastqsanger.gz
	SRR18148044_2.fastq.gz	Fastqsanger.gz
	SRR18148045_1.fastq.gz	Fastqsanger.gz
	SRR18148045_2.fastq.gz	Fastqsanger.gz
	SRR18148046_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

RNA-seq of OPM2 multiple myeloma cells treated with HDAC inhibitors panobinostat, romidepsin, and ricolinostat.

Project description:Histone deacetylase (HDAC) inhibitors have been reported to exert synergistic antitumor effects with immunomodulatory drugs (IMiDs) in multiple myeloma, although the underlying molecular mechanisms are not fully elucidated. To delineate pathways potentially involved in this synergy, we profiled gene expression changes induced by HDAC inhibition in the OPM2 multiple myeloma cell line. Cells were treated with panobinostat (10 nM), romidepsin (10 nM), or ricolinostat (100 nM) for 2, 5, or 20 hours, followed by RNA-seq analysis. Two independent biological replicates were generated for each condition. These data provide a resource for identifying HDAC inhibitor–responsive genes and pathways that may contribute to the cooperative activity of HDAC inhibitors and IMiDs in multiple myeloma.

2026-02-25 | GSE307106 | GEO

RNA-seq analysis after dBRD9-A treatment in human multiple myeloma cell line OPM2 and H929

Project description:RNA-seq analysis after dBRD9-A treatment in human multiple myeloma cell line OPM2 and H929

| PRJNA810495 | ENA

Effect of treatment OPM2 multiple myeloma cells with EPA, DHA or bortezomib

Project description:Effect of treatment OPM2 multiple myeloma cells with EPA, DHA or bortezomib

| PRJEB54097 | ENA

Gene Expression Profiling of OPM2 treatment with VS-5584 (SB2343).

Project description:The PI3K/mTOR pathway is a constitutively active in multiple myeloma. Single inhibition of mTOR usually confers reactivation of the pathway. VS-5584 (SB2343) is a bispecific PI3K/mTOR inhibitor which effectively and specifically inhibits the target pathways and shows potent anti-myeloma activity. We utilised a gene microarray analysis to analyse and identify the genes that were sensitively regulated by VS-5584 treatment in OPM2. OPM2 cells were either treated with DMSO(drug solvent) or with 125nM of VS-5584(SB2343) which is half the IC50 concentration of the drug at 48h in OPM2 cells. The cells were harvested at 24h in order to detect the regulation of relatively early response genes.

2016-07-27 | E-GEOD-84862 | biostudies-arrayexpress

Gene Expression Profiling of OPM2 treatment with VS-5584 (SB2343).

2016-07-27 | GSE84862 | GEO

Effect of treatment OPM2 multiple myeloma cells with EPA, DHA or bortezomib

Project description:OPM2 cells were seeded in a 12-well plate at density of 10 × 103 cells/well and incubated with the indicated concentrations of compounds. OPM2 cells were treated with 50 µM of DHA/EPA (6 h) or 10 nM of bortezomib (4 h). Total RNA was extracted from cells using RNeasy Mini Kit (74104, Qiagen, Hilden, Germany) and RNA integrity was determined by Agilent 2100 analysis. RNA integrity numbers (RIN) of all samples were greater than 8.0. RNA-seq libraries were prepared and sequenced at Novogene (Novogene, Cambridge, UK)

2022-06-26 | E-MTAB-11907 | biostudies-arrayexpress

Chip-seq analysis after dBRD9-A treatment in human multiple myeloma cell line OPM2

Project description:BRD9 is a defining component of the non-canonical SWI/SNF complex, regulating gene expression by controlling chromatin dynamics. We here identified high BRD9 expression as a poor prognostic factor in multiple myeloma (MM), which is positively correlated with activation of ribosome biogenesis. Genetic and pharmacological depletion of BRD9 downregulates expression of ribosome biogenesis genes and disrupts protein synthesis maintenance machinery, thereby inhibiting MM cell growth in both in vitro and in vivo preclinical models. Importantly, BRD9 interacts with BRD4 and MYC to form a transcription initiation complex that promotes transcription of ribosomal biogenesis genes. These results identify and validate BRD9 as a novel therapeutic target in MM which regulates ribosome biogenesis gene transcription, and provide the framework for clinical evaluation of BRD9 degraders to improve patient outcome in MM. This SuperSeries is composed of the SubSeries listed below.

2023-02-08 | GSE197486 | GEO

Effect of forkhead box M1 in multiple myeloma

Project description:Forkhead Box M1 (FOXM1) is a promising molecular target for high-risk multiple myeloma and relapse and refractory myeloma, but whether FOXM1 is essential in myeloma has not yet been established. To address this knowledge gap, we used Western blotting to measure FOXM1 protein levels in 11 human myeloma cell lines (HMCLs) and then chose the two lines expressing the largest amount of the transcription factor, OPM2 and Delta47, for gene editing using CRISPR-Cas9. In both cases, two independent FOXM1-deficient daughter lines, designated KO-1 and KO-2, were generated. They contained 2 different 10-bp deletions at the target site of their respective guide RNA in case of OPM2 and a 10-bp deletion and 1-bp insertion in case of Delta47. Western analysis confirmed the lack of FOXM1 in all knockout clones. FOXM1-deficient myeloma cells proliferated more slowly than their parental counterparts containing normal levels of FOXM1. Moreover, we added back FOXM1 to FOXM1-KO cells by transfection of a constitutively expressed FOXM1c cDNA gene. The reconstituted OPM2 and Delta47 cells, designated FOXM1 KO-R contained high amounts of FOXM1 protein. Here, we used these cell lines to investigate the role of FOXM1 in regulating the gene expression in multiple myeloma.

2021-07-14 | GSE180018 | GEO

Multiple myeloma

Project description:Multiple myeloma

| PRJNA515992 | ENA

RNA-seq analysis after dBRD9-A treatment in human multiple myeloma cell line OPM2 and H929

2023-02-08 | GSE197487 | GEO